PharmaEssentia Statistics

Total Valuation

PharmaEssentia has a market cap or net worth of EUR 5.11 billion. The enterprise value is 4.49 billion.

Market Cap	5.11B
Enterprise Value	4.49B

Important Dates

The next estimated earnings date is Tuesday, August 12, 2025.

Earnings Date	Aug 12, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	+1.10%
Shares Change (QoQ)	-0.18%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	262.18M

Valuation Ratios

The trailing PE ratio is 47.10 and the forward PE ratio is 25.55.

PE Ratio	47.10
Forward PE	25.55
PS Ratio	16.20
PB Ratio	6.31
P/TBV Ratio	6.36
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 48.22, with an EV/FCF ratio of 54.40.

EV / Earnings	41.39
EV / Sales	13.46
EV / EBITDA	48.22
EV / EBIT	54.03
EV / FCF	54.40

Financial Position

The company has a current ratio of 9.07, with a Debt / Equity ratio of 0.03.

Current Ratio	9.07
Quick Ratio	8.48
Debt / Equity	0.03
Debt / EBITDA	0.31
Debt / FCF	0.33
Interest Coverage	125.64

Financial Efficiency

Return on equity (ROE) is 14.56% and return on invested capital (ROIC) is 6.34%.

Return on Equity (ROE)	14.56%
Return on Assets (ROA)	5.86%
Return on Invested Capital (ROIC)	6.34%
Return on Capital Employed (ROCE)	9.39%
Revenue Per Employee	2.41M
Profits Per Employee	827,516
Employee Count	131
Asset Turnover	0.38
Inventory Turnover	0.94

Taxes

In the past 12 months, PharmaEssentia has paid 6.17 million in taxes.

Income Tax	6.17M
Effective Tax Rate	5.38%

Stock Price Statistics

The stock price has increased by +18.42% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+18.42%
50-Day Moving Average	16.64
200-Day Moving Average	18.94
Relative Strength Index (RSI)	54.10
Average Volume (20 Days)	n/a

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, PharmaEssentia had revenue of EUR 315.28 million and earned 108.40 million in profits. Earnings per share was 0.32.

Revenue	315.28M
Gross Profit	277.84M
Operating Income	78.52M
Pretax Income	114.57M
Net Income	108.40M
EBITDA	81.69M
EBIT	78.52M
Earnings Per Share (EPS)	0.32

Full Income Statement

Balance Sheet

The company has 612.68 million in cash and 27.39 million in debt, giving a net cash position of 585.29 million.

Cash & Cash Equivalents	612.68M
Total Debt	27.39M
Net Cash	585.29M
Net Cash Per Share	n/a
Equity (Book Value)	809.78M
Book Value Per Share	2.43
Working Capital	665.45M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 108.77 million and capital expenditures -26.28 million, giving a free cash flow of 82.48 million.

Operating Cash Flow	108.77M
Capital Expenditures	-26.28M
Free Cash Flow	82.48M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 88.12%, with operating and profit margins of 24.90% and 34.38%.

Gross Margin	88.12%
Operating Margin	24.90%
Pretax Margin	36.34%
Profit Margin	34.38%
EBITDA Margin	25.91%
EBIT Margin	24.90%
FCF Margin	26.16%

Dividends & Yields

PharmaEssentia does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-1.10%
Shareholder Yield	n/a
Earnings Yield	2.12%
FCF Yield	1.62%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

PharmaEssentia has an Altman Z-Score of 31 and a Piotroski F-Score of 6.

Altman Z-Score	31
Piotroski F-Score	6